Dallas、TXにおける悪性黒色腫の臨床試験
Dallasとその周辺地域（約30マイル以内）の拠点で、悪性黒色腫に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
被験者募集中第3相
- Texas Oncology - Medical City, Dallas
- Texas Oncology, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Baylor, Scott and White Research Institute, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- UT Southwestern Medical Center, Dallas
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
被験者募集中第1/2相
- UT Southwestern, Dallas
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
被験者募集中第1/2相
- Texas Oncology - Dallas SCRI, Dallas
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
被験者募集中第1/2相
- Texas Oncology, P.A., Dallas
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
被験者募集中第1/2相
- Call for Information (Investigational Site 0054), Dallas
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
被験者募集中観察研究
- University of Texas Southwestern Medical Center, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
Neoadjuvant Darovasertib in Primary Uveal Melanoma
被験者募集中第3相
- Texas Retina Associates - Dallas, Dallas
- University of Texas Southwestern Medical Center-5323 Harry Hines Blvd, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- UT Southwestern Medical Center, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
被験者募集中第1/2相
- Research Site, Dallas
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
被験者募集中第1相
- NEXT Dallas, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Dallas
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology, Dallas, Dallas
他の都市における悪性黒色腫の試験
- Houston, TX59件の研究
- New York City, NY38件の研究
- Los Angeles, CA34件の研究
- Nashville, TN33件の研究
- Pittsburgh, PA31件の研究
- Boston, MA26件の研究
- Philadelphia, PA23件の研究
- San Francisco, CA22件の研究
- Durham, NC21件の研究
- Atlanta, GA21件の研究
- St. Louis, MO21件の研究
- Salt Lake City, UT21件の研究
Dallasにおける他の研究
- 乳がん55件の研究
- 非小細胞肺癌52件の研究
- 転移性癌42件の研究
- 心不全42件の研究
- がん（全種類）37件の研究
- 前立腺がん36件の研究
- 大腸癌33件の研究
- 肥満症30件の研究
- 卵巣がん28件の研究
- 膀胱癌27件の研究
- 肺がん27件の研究
- 子宮内膜がん24件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。